Why You Should Invest in Europe’s Cannabis Industry (and Its Upcoming Leader)
April 25th, 2022
Exclusive, News, Top Story
The North American cannabis industry has struggled over the past couple of years, but fundamentals are improving and valuations are becoming attractive. As North America continues to grapple with excess supply issues, challenging margins and regulations, investors are starting to turn their attention toward European markets that are in the early innings of adoption and poised for hyper growth opportunities.
In this article, we’ll take a look at how to invest in Europe’s next cannabis leader, Franchise Global Health (TSX-V: FGH).
Europe is a Cash Cow Business
North America represents more than 95% of the $16.5 billion global legal cannabis market, according to Statista, but Europe offers far superior margins and significant long-term growth potential. As a result, companies operating in Europe could experience better economics than the saturated North American markets, as well as more long-term growth potential.
Currently, the average retail price of medical cannabis in Germany is almost 2-3x higher than major North American markets currently standing at C$30 per gram in Germany compared to C$13 in the U.S. and C$10 in Canada. Moreover, the German government fully reimburses 62% of medical cannabis patients through insurance schemes.
Germany’s move to legalize recreational cannabis over the coming quarters could pave the way for other European countries to do the same. With a larger population than the U.S. and Canada combined, Europe could become one of the fastest growing and largest cannabis markets in the world over the coming years as these trends unfold.
According to the Brightfield Group, Europe’s cannabis industry could reach $4 billion by 2025, nearing the $4.4 billion in sales in California—the largest single market in the world. And Germany alone could become a $1.2+ billion market over the same timeframe. These are significant numbers that investors cannot afford to ignore.
Leverage First-Mover Advantage
Franchise Global Health (TSX-V: FGH) has a clear first-mover advantage in Europe having received the very first import and distribution license in Germany, Franchise sold the first gram of medical cannabis in the country and is now selling to over 1,200 pharmacies. Strong relationships have been forged with this large network, which is critically important and a remarkable feat given the highly fragmented nature of the market.
In addition to their impressive retail network, Franchise is also selling over 700 skus of various pharmaceutical products to their mass pharma distribution networks which spans across 18 countries in the EU. This vast retail and wholesale operational footprint provides another competitive advantage to Franchise as they are favorably positioned to move quickly to capitalize on opportunities as market dynamics and regulations continue to progress.
The company has also secured 500,000 sq ft of reserved cultivation capacity and 30,000 sq ft of processing capacity at an EU GMP facility. This supply capacity could meet the demands of the growing European market and other global markets that are looking for consistent supplies of high quality EU GMP certified cannabis. These facilities are scalable up to 65,000 kilograms per year, which could also pave the way for significant revenue as European countries begin to explore and adopt recreational cannabis programs over the coming years.
Franchise Global Health (TSX-V: FGH) represents a compelling opportunity to invest in Europe’s next cannabis leader. In addition to its operational progress, its experienced management team has been a strong steward of capital, raising over $56 million in private equity to date, without any dilutive warrants affecting shareholders. This capital markets experience and expertise from Franchise’s leadership team will serve them well as strategic accretive M&A paired with organic growth are key pillars of their plan to continue to build long-term shareholder value.
The company also trades at an attractive valuation compared to its Canadian peers, including Tilray, Canopy Growth, Aurora, and others. For example, its CY22E TEV/Revenue multiple stands at just 2.0x, compared to 4.3x for its peer group. And its CY23E TEV/EBITDA multiple is projected at 18.3x versus a 29x peer average. Investors may want to pay close attention as the company works towards taking a foothold in Europe.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.